Drug intelligence / Profile preview

norgestimate + ethinyl estradiol + folic acid

Development stage
Preclinical
Lead developer
Janssen Research & Development
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

Norgestimate + ethinyl estradiol + folic acid is a combination oral contraceptive containing two synthetic hormones—norgestimate (a progestin) and ethinyl estradiol (an estrogen)—along with folic acid, a B-vitamin. The primary indication is the prevention of pregnancy. The contraceptive effect is achieved by inhibiting ovulation, altering cervical mucus to impede sperm penetration, and modifying the endometrial lining to reduce the likelihood of implantation. Norgestimate acts as a prodrug that is metabolized into active metabolites after oral administration. Ethinyl estradiol increases sex hormone-binding globulin levels and both components are extensively protein-bound in plasma[1][2][5]. Folic acid supplementation in these formulations aims to reduce the risk of neural tube defects should conception occur shortly after discontinuation.

02

Targets

PR (Progesterone receptor)ER (Estrogen receptor)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on norgestimate + ethinyl estradiol + folic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on norgestimate + ethinyl estradiol + folic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call